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Breast cancer is the most common global malignancy found in women and likewise so in Poland; newly diagnosed 
cases being respectively ≈ 1.7 million and 17 thousand annually. For the last 30 years, population screening has been 
adopted in the developed world. In Poland, breast screening attendance is however around 45%, what is still lower 
than in highly developed countries (above 70%). Breast cancer mortality has also declined more slowly in Poland. 
Following the introduction of breast screening, the rapid decreases in mortality demonstrated in Western Europe 
and the USA prove its effectiveness. Observations and data accumulated over many years through screening have 
nevertheless generated debate regarding overdiagnosis and overtreatment of breast cancer. This issue has been 
summarised in the WHO Position Paper that recommends continuing breast screening whilst also ensuring that 
patients are able to make informed decisions. 
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Two opposing points of view were put forward during the 
debate on controversies arising around the issue of mammo-
graphic breast cancer screening, as organised by the Nowot-
wory Journal of Oncology: recognising screening as standard 
practice and doubts on the validity of such procedure.
Faced with the current state of knowledge, along with cur-
rent practices in many countries and the WHO’s position [1], 
population screening is undoubtedly a standard procedure 
at present in all highly developed countries of the world.
Assessment of population screening merits is based on 
literature review. Data on cancer incidence and mortality 
come from universally available epidemiological databases 
in both the world and Poland [2–5]. 
Discussions on this subject should start by presenting 
the scale of the problem. After lung cancer, breast cancer is 
the second most common malignancy in the world and the 
most common cancer in women; in 2012 cancer incidence 
was ≈ 1.7 million what constituted ¼ of cancer in women. 
Breast cancer is the most common cancer in both devel-
oped and less well-developed countries with respective 
incidence rates of ≈ 883,000 and 794,000. Incidence rates 
greatly vary according to region: ≈ 10/105 in some African 
countries (Gambia, Gabon, Rwanda) and Eastern Asia but 
are 100/105 in the affluent countries of Europe (Belgium, 
Denmark) [1]. Breast cancer is responsible for half a million 
women’s deaths worldwide (5 causes ranked at 15%). It is 
a more frequent cause of death (20%) in countries of low Hu-
man Development Index (HDI) compared to countries with 
a high HDI (17%). Differences in mortality between regions 
are less than those for incidence, where the former varies 
from 6/105 in the Far East to 20/105 in Western Africa [2, 5]. 
In Poland, breast cancer is also the most common ma-
lignancy, constituting respectively 22% and 15% of can-
cer incidence and mortality. Over 17.2 thousand women 
must face up to receiving a breast cancer diagnosis, and 
5.3 thousand die as a result. The problem of breast cancer 
in Poland intensifies when mortality rates are compared to 
those overall; 9% mortality in young women aged 20–44 
years and 14% in middle-aged women (45–64 years) are 
due to breast cancer [3, 4].
As breast cancer is such a serious problem, choosing 
the best strategy for prevention and dealing with its con-
sequences becomes necessary. For many years a general 
scheme for optimal conduct regarding cancer has been: 
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prevention, early detection and effective treatment. What 
can be achieved in the primary prevention of breast cancer?
Primary prevention is most effective in those diseases 
for which the risk factors are known so that modifying meas-
ures taken, can have a real impact on the behaviour of the 
population. In the case of breast cancer, women’s risk factors 
are both constitutional (age at menarche, menopause) and 
lifestyle behaviour (weight, physical activity, alcohol con-
sumption), together with decisions made on intimate mat-
ters (taking contraceptives, childbirth age, breast feeding, 
number of labours, taking Hormone Replacement Therapy 
— HRT). From the known risk factors, only exposure to 
HRT has been limited following publication of the Women’s 
Health Initiative’s findings [6]. In the USA, a threefold de-
crease in the number of HRT prescriptions over 2001–2003 
resulted in immediate decrease of incidence in 2003, to 
10/105 women [7]. Data from Poland on HRT are very limited, 
and one can only expect that after the 1989 changes, cou-
pled with pharmaceutical marketing and developments in 
pharmaceuticals, women born post World War II have easier 
access to such drugs. Despite the visible effects of the other 
aforementioned risk factors shown by ecological studies, 
they are difficult to modify and, quite probably, several 
need to be changed simultaneously. Therefore, perhaps 
secondary prevention (screening) may limit the societal 
consequences of breast cancer? 
Poland was one of the countries that introduced screen-
ing in 2006, which compared to Western countries was 20 
years behind. Participation of Polish women in screening 
programmes is still twice lower than in Western Europe and 
the USA. Currently, participation in screening programmes 
in Poland after 10 years stands at 45%, whilst for the USA 
and Western Europe this ranges at 70–80% [8]. The effective-
ness of screening programmes started to be assessed after 
30 years of observation; the 10 years observation period in 
Poland therefore precludes any assessment of efficiency or 
effectiveness. 
Can the strategy for protecting women against breast 
cancer be solely based on the assumption that treating this 
disease is sufficiently effective? Breast cancer survival rates in 
highly developed countries exceeds 85%. Poland’s five year 
survival rates are around 10% lower; 74% of those diagnosed 
with the disease during 2005–2009, which is higher only in 
Latvia (71%), Estonia, Lithuania and Slovakia (72%) [9]. Can 
these differences be explained by the belated introduction 
of screening in Poland and the Baltic countries? 
In those countries that introduced screening in the 
1980–1990s, and where participation is high, survivals are 
also higher. If so, why are the merits of screening now been 
increasingly questioned. The criteria put forward by Wilson 
& Junger in 1968 still remain in force for assessing screen-
ing. Breast cancer screening fulfils most of these criteria (an 
important health and societal problem; the possibility for 
curing and/or improved treatment outcomes at early stages; 
the preclinical phase for easy detection and treatment; ap-
propriate and accepted tests being repeated from the time 
risk becomes recognised; defining a high risk sub-popula-
tion; benefits exceeding the risk; population study costs 
not exceeding those for treatment). Doubts only become 
apparent when determining the natural disease-course 
history, where most of the reservations on breast cancer 
screening are directly related to this issue. 
Introducing population-based screening was founded 
on the premise that breast cancer progression occurs in 
a ‘linear’ fashion. In such linear models, it is assumed that 
the tumour stably (uniformly) develops with time, creating 
a chain of events occurring in a defined and predictable 
manner, (starting from the atypical or in situ stages and 
terminating in metastases and death), and thus making an 
early diagnosis vital for decreasing mortality [10]. As from 
several years now, this linear model of breast cancer devel-
opment is being cast aside in favour of models composed of 
different scenarios. An analysis of the actual disease course 
in several thousand so-affected patients allowed for creating 
a theoretical stochastic model, which shows that the way tu-
mours progress can significantly impact on the advantages 
derived from screening [11]. Many studies indicate that 
a given tumour development follows various scenarios in 
accordance to its biology. A ‘variation’ model distinguishes 
three basic types of scenarios: indolent/regressive, slow 
and rapid, however the actual development course can be 
mixed. In the first case, the indolent/regressive, cell transfor-
mation is very slow or lesions can actually regress; so such 
women derive no benefit from being screened. The ‘slow’ 
scenario is identified with the classic linear model of breast 
cancer development; mortality rates become reduced as 
a result of screening in such cases. In those women where 
the disease course is ‘rapid’, there is a high likelihood of inter-
val cancer where any benefits in screening are limited (Fig. 1).
Within the last decade the issue of overdiagnosing 
breast cancer has been debated regarding the screening, 
which is also linked to over-treatment. The key issue is over-
diagnosis. The simplest and most intuitive definition of this 
term can be: diagnosing disease status, that would never 
give symptoms arising or lead to death. It seems likely that 
such terminology can only be correctly applied to those 
women at the ‘indolent/regressive’ scenarios of breast can-
cer. The above definition tacitly infers that there are high-
-probability methods for detecting persons with indolent/ 
/regressive tumours leading to overdiagnosis. However, it 
seems that the problem is that we lack sufficient knowledge, 
that could allow classifying women as having indolent/ 
/regressive tumours. Of course certain necessary conditions 
exists for defining the likelihood of developing one of the 
aforementioned scenarios, but the risk of committing an 
error is still large. 
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Because many patients are overdiagnosed, (which is the 
main complaint levelled at screening), then, should they 
be treated, and if so, should this be considered as an over-
treatment? The most frequent diagnosis, that is evoked as 
‘overdiagnosis’ is Ductal carcinoma in situ. Some researchers 
and practioners wish to consider in situ cancer as an over-
diagnosis. Yet the question on how to conduct treatment in 
such cases is debated in the most of the respected medical 
journals. Some recommend 30 minutes of daily physical 
exercise, but others say that the excellent outcomes of treat-
ing in situ cancer does not translate to equally favourable 
therapeutic outcomes without treatment, and thus treat-
ment is indeed required [12]. 
A compelling argument for exercising caution about 
in situ cancer is the association between the incidence of 
discovering interval cancers with the incidence of detect-
ing in situ cancer. A study by Duffy [13] demonstrated that 
in 1000 women taking part in screening, the increase in 
detecting Ductal carcinoma in situ from below 1 to over 2 is 
linked with an 11% decrease in detecting interval cancers. 
These studies have led to a functional relationship being 
established, indicating an inversely proportional relation-
ship between detecting the incidence of in situ cancer and 
the incidence of invasive interval cancers. 
A literature review assessing European screening stud-
ies by Paci et al., showed that reduced mortality in women 
taking part in screening varies from 38% (IBM sties) to 48% 
(clinical-control studies). Contemporaneously, overdiagno-
ses adjusted for lead time and breast cancer risk was esti-
mated at being 1–10% (adjusted mean = 6.5%). A balance 
of account put forward by researchers shows that for every 
1000 women screened biannually aged, 50–69 years and up 
to 79 years of age, then it is possible to prevent mortality 
in 7–9 women, as compared to 30 such deaths without any 
screening at all, whilst 4 women are overdiagnosed [14].
The recommendations of the Guideline Development 
Group (GDG), that prepared the WHO position on breast 
cancer screening (according to GRADE methodology) with 
regards to a country’s socio-economic development, ad-
vocate undertaking a mammography programme in those 
countries where a well developed national health service 
exists (including Poland), consisting of screening women 
aged 50–69 years, every 2 years. The GDG working group 
emphasises that the organisers of screening studies should 
have a strategic plan ready for informing women, in an ob-
jective and balanced fashion, about the benefits and risks 
of taking part in mammography screening, where women’s 
decisions should agree with their preferred choices and be 
made with their full awareness [1]. 
I consider that the WHO position, best represents today’s 
knowledge and most importantly emphasises the empow-
ering of women. It is the woman who should decide for 
herself whether to be screened on the basis of objective in-
formation, and her participation should be accommodated 
under a caring and hospitable environment. Breast cancer 
screening is a standard procedure in all developed countries 
and it is hoped that this likewise remains the case in Poland. 
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Figure 1. Theoretical scenarios of breast cancer development
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